Axsome Therapeutics (NASDAQ: AXSM) has built a compelling track record in the neuroscience space, targeting conditions tied to central nervous system operations including depression, migraine, and narcolepsy.
The stock climbed 180% over three years as investors responded to new product approvals, pipeline progress, and sustained double-digit revenue growth across the company’s portfolio.
Despite that impressive run, AXSM shares have pulled back roughly 15% over the past three months, raising a timely question about whether the dip represents a buying opportunity.
Axsome currently markets three commercialized drugs, with its lead product Auvelity approved for major depressive disorder in 2022 and more recently cleared for agitation associated with Alzheimer’s disease.
Auvelity sales jumped more than 50% in the most recent quarter to approximately $180 million, with the Alzheimer’s agitation approval immediately broadening the drug’s revenue opportunity in a significant way.
Following its June launch into the Alzheimer’s market, new-to-brand Auvelity prescriptions among adults aged 65 and older increased 126% in the first eight weeks compared to the same period in the prior quarter.
Total Auvelity prescriptions written during the quarter rose 34% year-over-year to 266,000, reinforcing the commercial momentum building across both approved indications for the drug.
Sunosi, the company’s treatment for excessive daytime sleepiness linked to narcolepsy or sleep apnea, saw a 14% year-over-year prescription increase to 61,000, generating net product revenue including royalties of more than $35 million.
Symbravo, a migraine treatment that launched in June of last year, recorded a 30% prescription increase from the first quarter to 23,500, with sales surging more than 400% to $2.3 million as payer coverage stands at 57% with room to expand.
The company is also completing additions to its Symbravo sales force, a move expected to extend its reach further into both primary care and specialist communities in the months ahead.
Axsome’s growth story extends well beyond its current marketed products, with five active phase 3 programs targeting attention deficit and hyperactivity disorder, major depressive disorder, binge eating disorder, shift work disorder, and fibromyalgia.
The company is also awaiting a regulatory decision on its narcolepsy candidate, with regulators expected to decide by May of next year, potentially adding another meaningful revenue driver to the portfolio.
Axsome recently stated that it expects its current cash position to fund operations through to cash flow positivity, a financial milestone that meaningfully reduces risk for shareholders considering an entry at current levels.
The combination of three revenue-generating products, a robust late-stage pipeline, and a strengthening balance sheet gives Axsome characteristics that appeal to both growth-focused and more cautious investors alike.
With a recent pullback creating a more attractive entry point and multiple potential catalysts on the horizon, AXSM presents a case worth serious consideration for investors watching the biopharma sector closely.
